Valproic acid (CAS 99-66-1) — formula C8H16O2, molecular weight 144.21; category organic chemicals.
| CAS Number | 99-66-1 |
|---|---|
| Molecular Formula | C8H16O2 |
| Molecular Weight | 144.21 |
| Boiling Point | 428 °F at 760 mmHg (NTP, 1992) |
| LogP | 2.8 |
| Applications | Uses: Indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur in either isolation or association with other types of seizures, THERAPEUTIC CATEGORY (VETERINARY): Anticonvulsant, MEDICATION, Anticonvulsants, Antimanic Agents, Enzyme Inhibitors, GABA Agents, Use (kg) in Switzerland (2009): >7500, Use (kg, approx.) in Germany (2009): >75000, exact) in Germany (2009): 94896, Use (kg) in USA (2002): 229000, Use (kg) in France (2004): 112162, Consumption (g per capita) in Switzerland (2009): 0.96, Consumption (g per capita, approx.) in Germany (2009): 0.92, exact) in Germany (2009): 1.2, Consumption (g per capita) in the USA (2002): 0.81, Consumption (g per capita) in France (2004): 1.9, Excretion rate: 0.02, Calculated removal (%): 93.6, For treatment and management of seizure disorders, mania, and prophylactic treatment of migraine headache. In epileptics, valproic acid is used to control absence seizures, tonic-clonic seizures (grand mal), complex partial seizures, and the seizures associated with Lennox-Gastaut syndrome (A308)., Use Classification: Pharmaceuticals, Methods of Manufacturing: Valproic acid may be synthesized from 4-heptanol by successive conversions to 4-bromoheptane with HBr, to 4-cyanoheptane with HCN and to 2-propyl pentanoic (valproic) acid by alkaline hydrolysis of the 4-cyanoheptane., Ethyl cyanoacetate + n-propyl bromide (dehydrobromination, decarboxylation, nitrile hydrolysis)., Formulations, Preparations: Oral: Solution: 250 mg (of valproic acid) per 5 mL Depakene Syrup (with parabens), (Abbott). Parenteral: Injection, for IV use: 100 mg (of valproic acid) per mL Depacon (with edetate disodium), (Abbott), Valproate Sodium Injection (with edetate disodium), (Abraxis), (Bedford)., Valproate sodium, Oral: Capsules, liquid-filled: 250 mg Depakene (with parabens), (Abbott)., Oral: Capsules (containing coated particles): equivalent to valproic acid 125 mg Depakote Sprinkle, (Abbott). Tablets, delayed-release: equivalent to valproic acid 125 mg Depakote (with povidone), equivalent to valproic acid 250 mg Depakote (with povidone), equivalent to valproic acid 500 mg Depakote (with povidone), extended-release: equivalent to valproic acid 250 mg Depakote ER, (Abbott) equivalent to valproic acid 500 mg Depakote ER, Divalproex sodium |
| Category | Organic Chemicals |
Documented applications: Uses: Indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur in either isolation or association with other types of seizures, THERAPEUTIC CATEGORY (VETERINARY): Anticonvulsant, MEDICATION, Anticonvulsants, Antimanic Agents, Enzyme Inhibitors, GABA Agents, Use (kg) in Switzerland (2009): >7500, Use (kg, approx.) in Germany (2009): >75000, exact) in Germany (2009): 94896, Use (kg) in USA (2002): 229000, Use (kg) in France (2004): 112162, Consumption (g per capita) in Switzerland (2009): 0.96, Consumption (g per capita, approx.) in Germany (2009): 0.92, exact) in Germany (2009): 1.2, Consumption (g per capita) in the USA (2002): 0.81, Consumption (g per capita) in France (2004): 1.9, Excretion rate: 0.02, Calculated removal (%): 93.6, For treatment and management of seizure disorders, mania, and prophylactic treatment of migraine headache. In epileptics, valproic acid is used to control absence seizures, tonic-clonic seizures (grand mal), complex partial seizures, and the seizures associated with Lennox-Gastaut syndrome (A308)., Use Classification: Pharmaceuticals, Methods of Manufacturing: Valproic acid may be synthesized from 4-heptanol by successive conversions to 4-bromoheptane with HBr, to 4-cyanoheptane with HCN and to 2-propyl pentanoic (valproic) acid by alkaline hydrolysis of the 4-cyanoheptane., Ethyl cyanoacetate + n-propyl bromide (dehydrobromination, decarboxylation, nitrile hydrolysis)., Formulations, Preparations: Oral: Solution: 250 mg (of valproic acid) per 5 mL Depakene Syrup (with parabens), (Abbott). Parenteral: Injection, for IV use: 100 mg (of valproic acid) per mL Depacon (with edetate disodium), (Abbott), Valproate Sodium Injection (with edetate disodium), (Abraxis), (Bedford)., Valproate sodium, Oral: Capsules, liquid-filled: 250 mg Depakene (with parabens), (Abbott)., Oral: Capsules (containing coated particles): equivalent to valproic acid 125 mg Depakote Sprinkle, (Abbott). Tablets, delayed-release: equivalent to valproic acid 125 mg Depakote (with povidone), equivalent to valproic acid 250 mg Depakote (with povidone), equivalent to valproic acid 500 mg Depakote (with povidone), extended-release: equivalent to valproic acid 250 mg Depakote ER, (Abbott) equivalent to valproic acid 500 mg Depakote ER, Divalproex sodium.
Valproic acid is a carbon-based organic compound with CAS registry number 99-66-1 and molecular formula C8H16O2 (molecular weight 144.21), belonging to the organic chemicals segment of chemical raw materials.
CAS number: 99-66-1
Its molecular formula C8H16O2 comprises 8 C, 16 H, 2 O atoms.
Also known as: Valproic acid · 丙戊酸 · 2,2-Di-n-propylacetic acid
Category: organic chemicals
The CAS registry number of Valproic acid is 99-66-1.
Molecular formula C8H16O2, molecular weight 144.21.
It is also registered under: Valproic acid, 丙戊酸, 2,2-Di-n-propylacetic acid.
Recorded applications: Uses: Indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur in either isolation or association with other types of seizures, THERAPEUTIC CATEGORY (VETERINARY): Anticonvulsant, MEDICATION, Anticonvulsants, Antimanic Agents, Enzyme Inhibitors, GABA Agents, Use (kg) in Switzerland (2009): >7500, Use (kg, approx.) in Germany (2009): >75000, exact) in Germany (2009): 94896, Use (kg) in USA (2002): 229000, Use (kg) in France (2004): 112162, Consumption (g per capita) in Switzerland (2009): 0.96, Consumption (g per capita, approx.) in Germany (2009): 0.92, exact) in Germany (2009): 1.2, Consumption (g per capita) in the USA (2002): 0.81, Consumption (g per capita) in France (2004): 1.9, Excretion rate: 0.02, Calculated removal (%): 93.6, For treatment and management of seizure disorders, mania, and prophylactic treatment of migraine headache. In epileptics, valproic acid is used to control absence seizures, tonic-clonic seizures (grand mal), complex partial seizures, and the seizures associated with Lennox-Gastaut syndrome (A308)., Use Classification: Pharmaceuticals, Methods of Manufacturing: Valproic acid may be synthesized from 4-heptanol by successive conversions to 4-bromoheptane with HBr, to 4-cyanoheptane with HCN and to 2-propyl pentanoic (valproic) acid by alkaline hydrolysis of the 4-cyanoheptane., Ethyl cyanoacetate + n-propyl bromide (dehydrobromination, decarboxylation, nitrile hydrolysis)., Formulations, Preparations: Oral: Solution: 250 mg (of valproic acid) per 5 mL Depakene Syrup (with parabens), (Abbott). Parenteral: Injection, for IV use: 100 mg (of valproic acid) per mL Depacon (with edetate disodium), (Abbott), Valproate Sodium Injection (with edetate disodium), (Abraxis), (Bedford)., Valproate sodium, Oral: Capsules, liquid-filled: 250 mg Depakene (with parabens), (Abbott)., Oral: Capsules (containing coated particles): equivalent to valproic acid 125 mg Depakote Sprinkle, (Abbott). Tablets, delayed-release: equivalent to valproic acid 125 mg Depakote (with povidone), equivalent to valproic acid 250 mg Depakote (with povidone), equivalent to valproic acid 500 mg Depakote (with povidone), extended-release: equivalent to valproic acid 250 mg Depakote ER, (Abbott) equivalent to valproic acid 500 mg Depakote ER, Divalproex sodium.
Category: Organic Chemicals.
Independent reference data for Valproic acid (CAS 99-66-1), compiled from public chemistry databases.
| CAS Registry Number | 99-66-1 |
|---|---|
| PubChem CID | 3121 |
| Molecular formula | C8H16O2 |
| IUPAC name | 2-propylpentanoic acid |
| UNII (FDA) | 614OI1Z5WI |
| Molecular Weight | 144.21 |
|---|---|
| XLogP3 | 2.8 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 5 |
| Exact Mass | 144.115029749 |
| Monoisotopic Mass | 144.115029749 |
| Topological Polar Surface Area | 37.3 |
| Heavy Atom Count | 10 |
| Boiling Point | 428 °F at 760 mmHg (NTP, 1992) |
|---|---|
| Boiling Point | 222 |
| Boiling Point | 219.5 °C |
| Boiling Point | BP: 219 to 220 °C |
| Boiling Point | 222 °C |
| Flash Point | 232 °F (NTP, 1992) |
| Solubility | 1.3 |
| Solubility | In water, 2.0X10+3 mg/L at 20 °C |
| Solubility | 2 mg/mL at 20 °C |
| Density | 0.904 g/cu cm at 25 °C |
VALPROIC ACID; 2-Propylpentanoic acid; 99-66-1; 2-Propylvaleric acid; Dipropylacetic acid; Depakene; Depakine; Mylproin; Di-n-propylacetic acid; Propylvaleric acid; n-Dipropylacetic acid; 4-Heptanecarboxylic acid; Myproic Acid; Convulex; n-DPA; Acido valproico
| Reported hazard statements | H302 (100%), H315 (92.9%), H318 (12.7%), H319 (80.2%), H335 (31.7%), H360 (64.3%), H336, H362 |
|---|
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
H315 (92.9%): Causes skin irritation [Warning Skin corrosion/irritation]
2,2-Di-n-propylacetic acid · CAS 99-66-1 · C8H16O2. UNII 614OI1Z5WI. Boiling Point: 428 °F at 760 mmHg (NTP, 1992); Boiling Point: 222; Boiling Point: 219.5 °C.
Source: PubChem / Wikidata; the batch COA governs where values differ.
Supplier: Jinan Shenghe Chemical Co., Ltd.
中文页面: 丙戊酸